Skip to main content
. 2021 Jul 16;118(9):2085–2102. doi: 10.1093/cvr/cvab240

Figure 3.

Figure 3

cGMPopathies and evidence-based therapies. Potential combinatorial cGMP therapies in cardiovascular applications. Blue dashed lines show drugs in clinical trials, whereas solid blue lines approved drugs. Red lines show limitations of usage in these indications. ARNI, angiotensin receptor-neprilysin inhibitor; GC-A/Bs, GC-A/B stimulators; NOd, NO donors; HNOd, nitroxyl donors; NOSr, NOS recoupling drugs; PDEi, PDE inhibitors; sGCs/a, sGC stimulators/activators. Created with BioRender.com.